Realizing individualized medicine: the road to translating proteomics from the laboratory to the clinic

被引:1
作者
Rahbar, Amir [1 ]
Rivers, Robert [1 ]
Boja, Emily [1 ]
Kinsinger, Christopher [1 ]
Mesri, Mehdi [1 ]
Hiltke, Tara [1 ]
Rodriguez, Henry [1 ]
机构
[1] NCI, Off Canc Clin Proteom Res, Ctr Strateg Sci Initiat, NIH, Bethesda, MD 20892 USA
关键词
biomarkers; diagnostics; enzyme-linked immunosorbent assay; individualized medicine; mass spectrometry; proteins; proteomics; TANDEM MASS-SPECTROMETRY; CELL LUNG-CANCER; LINKED-IMMUNOSORBENT-ASSAY; ANTIBODY-BASED PROTEOMICS; LIQUID-CHROMATOGRAPHY; QUANTITATIVE-ANALYSIS; BIOMARKER DISCOVERY; NEXT-GENERATION; PLASMA PROTEOME; FUTURE FIELDS;
D O I
10.2217/PME.10.76
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The sequencing of the human genome has brought great promise and potential for the future of medicine, as well as providing a strong momentum for the burgeoning field of individualized medicine. Tests based on genetic information can be used to allow physicians to target therapies for those patients most likely to benefit from specific therapies and identify potential risk before the onset of disease. While advances in genomics-based molecular diagnostics are progressing, producing some useful US FDA-approved/-cleared diagnostic tests, protein-based molecular diagnostics have not met its promised potential. This article will provide an overview of protein-based analysis technologies, identify their strengths and limitations, discuss barriers to protein-based biomarker development and identify issues which must be addressed in order to successfully transfer the field of proteomics from the laboratory to the clinic.
引用
收藏
页码:45 / 57
页数:13
相关论文
共 91 条
  • [11] Epidermal growth factor receptor inhibitors and their role in non-small-cell lung cancer
    Byrne B.J.
    Garst J.
    [J]. Current Oncology Reports, 2005, 7 (4) : 241 - 247
  • [12] A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses
    Cameron, David
    Casey, Michelle
    Press, Michael
    Lindquist, Deborah
    Pienkowski, Tadeusz
    Romieu, C. Gilles
    Chan, Stephen
    Jagiello-Gruszfeld, Agnieszka
    Kaufman, Bella
    Crown, John
    Chan, Arlene
    Campone, Mario
    Viens, Patrice
    Davidson, Neville
    Gorbounova, Vera
    Raats, Johannes Isaac
    Skarlos, Dimosthenis
    Newstat, Beth
    Roychowdhury, Debasish
    Paoletti, Paolo
    Oliva, Cristina
    Rubin, Stephen
    Stein, Steven
    Geyer, Charles E.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2008, 112 (03) : 533 - 543
  • [13] Canas Benito, 2006, Briefings in Functional Genomics & Proteomics, V4, P295, DOI 10.1093/bfgp/eli002
  • [14] Molecular imaging of biological samples: Localization of peptides and proteins using MALDI-TOF MS
    Caprioli, RM
    Farmer, TB
    Gile, J
    [J]. ANALYTICAL CHEMISTRY, 1997, 69 (23) : 4751 - 4760
  • [15] Cottingham Katie, 2009, J Proteome Res, V8, P4887, DOI 10.1021/pr900912g
  • [16] Cregger M, 2006, ARCH PATHOL LAB MED, V130, P1026
  • [17] Gene expression profiling: Decoding breast cancer
    de Snoo, Femke
    Bender, Richard
    Glas, Annuska
    Rutgers, Emiel
    [J]. SURGICAL ONCOLOGY-OXFORD, 2009, 18 (04): : 366 - 378
  • [18] mzML: A single, unifying data format for mass spectrometer output
    Deutsch, Eric
    [J]. PROTEOMICS, 2008, 8 (14) : 2776 - 2777
  • [19] Deutzmann Rainer, 2004, Methods Mol Med, V94, P269
  • [20] Review - Mass spectrometry and protein analysis
    Domon, B
    Aebersold, R
    [J]. SCIENCE, 2006, 312 (5771) : 212 - 217